The Beauty Health Company (SKIN)
- Previous Close
1.6400 - Open
1.6500 - Bid 1.5300 x 100
- Ask 1.5600 x 500
- Day's Range
1.5200 - 1.6500 - 52 Week Range
0.9100 - 6.7900 - Volume
127,938 - Avg. Volume
1,653,548 - Market Cap (intraday)
190.991M - Beta (5Y Monthly) 0.96
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8300 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
3.08
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a Delivery System designs to connects providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive, a treatment for scalp health. The company was founded in 1997 and is headquartered in Long Beach, California.
www.beautyhealth.com881
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: SKIN
View MorePerformance Overview: SKIN
Trailing total returns as of 9/18/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SKIN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SKIN
View MoreValuation Measures
Market Cap
203.39M
Enterprise Value
421.46M
Trailing P/E
--
Forward P/E
27.32
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.61
Price/Book (mrq)
2.94
Enterprise Value/Revenue
1.15
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-22.85%
Return on Assets (ttm)
-10.15%
Return on Equity (ttm)
-72.46%
Revenue (ttm)
366.23M
Net Income Avi to Common (ttm)
-83.7M
Diluted EPS (ttm)
-0.8300
Balance Sheet and Cash Flow
Total Cash (mrq)
349.54M
Total Debt/Equity (mrq)
820.37%
Levered Free Cash Flow (ttm)
29.01M